Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. | Merck & ...

MBX has fleshed out plans to take in over $136 million from its IPO as the biotech looks to bring a potential challenger to ...

He is now chairman, president and CEO of Candid Therapeutics, which has debuted with a $370 million series A and a goal to ...

GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...

The orthopedic robotics developer Think Surgical has collected its third FDA clearance in as many months, with a specialized ...

Ahead of the readout, Relay identified the 5.5-month progression-free survival (PFS) seen in a study of AstraZeneca’s Truqap ...

Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data ...

Some patients with non-small cell lung cancer (NSCLC) have mutations in a gene called human epidermal growth factor receptor 2 (HER2), which drives their disease progression. | Some patients with ...

Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its ...

The palms of our hands and the bottoms of our feet aren’t the flashiest body parts, but they have a secret superpower that we don’t often appreciate—the ability to bear weight. | For those with ...